Skip Navigation



Annals of Oncology Advance Access published online on February 17, 2008
Annals of Oncology, doi:10.1093/annonc/mdm601
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/6/1068    most recent
mdm601v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Burstein, H. J.
Right arrow Articles by Blackwell, K. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burstein, H. J.
Right arrow Articles by Blackwell, K. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2008 European Society for Medical Oncology. For Permissions, please email: journals.permissions@oxfordjournals.org

A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer

H. J. Burstein1,*, A. M. Storniolo2, S. Franco3, J. Forster4, S. Stein4, S. Rubin4, V. M. Salazar4 and K. L. Blackwell5

1 Medical Oncology, Dana Farber Cancer Institute, Boston, MA
2 Oncology, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
3 Oncology, Memorial Cancer Institute, Hollywood, FL
4 Medicine Development Center Oncology, GlaxoSmithKline, Collegeville, PA
5 Oncology, Duke University Medical Center, Durham, NC, USA

* Correspondence to: Dr H. J. Burstein, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA. Tel: +1-617-632-2624; Fax: +1-617-632-1930; E-mail: hburstein{at}partners.org

Background: The efficacy and tolerability of the epidermal growth factor receptor/human epidermal growth factor receptor type 2 (HER2) tyrosine kinase inhibitor lapatinib in refractory metastatic breast cancer were assessed.

Patients and methods: In a phase II, open-label study, patients with previously treated HER2-positive (n = 140) or HER2-negative (n = 89) metastatic breast cancer received once-daily oral lapatinib 1500 mg/day.

Results: Most (76%) patients had received four or more lines of prior therapy. The response rate in the HER2-positive cohort was 4.3% by investigator assessment and 1.4% by independent assessment. Both assessments established that ~6% of HER2-positive patients derived clinical benefit from lapatinib, being progression free for ≥6 months. No objective tumor responses occurred in the HER2-negative cohort. Independent review assessments of median time to progression and median progression-free survival were similar in the HER2-positive and HER2-negative cohorts (9.1 and 7.6 weeks, respectively). All responders exhibited HER2 overexpression (3+ by immunohistochemistry), and five of six responders were HER2 amplified by FISH. Lapatinib-related adverse events, including diarrhea (54%), rash (30%), and nausea (24%), were primarily mild to moderate in severity.

Conclusions: Lapatinib monotherapy had modest clinical activity in HER2-positive metastatic breast cancer that progressed on prior trastuzumab regimens. No apparent clinical activity was observed in chemotherapy-refractory, HER2-negative disease.

breast cancer, EGFR, ErbB2, targeted therapy, tyrosine kinase inhibitor, trastuzumab

Received for publication December 13, 2007. Accepted for publication December 17, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
S. Beslija, J. Bonneterre, H. J. Burstein, V. Cocquyt, M. Gnant, V. Heinemann, J. Jassem, W. J. Kostler, M. Krainer, S. Menard, et al.
Third consensus on medical treatment of metastatic breast cancer
Ann. Onc., November 1, 2009; 20(11): 1771 - 1785.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
N. Normanno, A. Morabito, A. De Luca, M. C. Piccirillo, M. Gallo, M. R Maiello, and F. Perrone
Target-based therapies in breast cancer: current status and future perspectives
Endocr. Relat. Cancer, September 1, 2009; 16(3): 675 - 702.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. S. Ross, E. A. Slodkowska, W. F. Symmans, L. Pusztai, P. M. Ravdin, and G. N. Hortobagyi
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
Oncologist, April 1, 2009; 14(4): 320 - 368.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. U. Lin, V. Dieras, D. Paul, D. Lossignol, C. Christodoulou, H.-J. Stemmler, H. Roche, M. C. Liu, R. Greil, E. Ciruelos, et al.
Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer
Clin. Cancer Res., February 15, 2009; 15(4): 1452 - 1459.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.